Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Smith & Nephew's Study Outcomes for REGENETEN Encouraging

by Zacks Equity Research

Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.

Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.

Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.

Medtronic (MDT) Beats on Q2 Earnings, Ups FY20 EPS Guidance

by Zacks Equity Research

Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.

Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath

by Zacks Equity Research

Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.

QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes

by Zacks Equity Research

QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.

Amedisys Partners With nVoq to Improve Clinician Experience

by Zacks Equity Research

Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.

Canopy Growth (CGC) Q2 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Canopy Growth (CGC) reports mixed fiscal second-quarter results on strength in its core segments.

Haemonetics (HAE) Grows on New Products, Robust Plasma Sales

by Zacks Equity Research

Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.

Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Insulet (PODD) has been gaining from several positive developments recently.

Here's Why You Should Hold on to CVS Health (CVS) For Now

by Zacks Equity Research

Investors can still hold on to CVS Health (CVS) stock, thanks to its solid prospects.

CVS Health's New Plans With Aetna May Improve Health Outcomes

by Zacks Equity Research

CVS Health's (CVS) Health Care Benefits segment develops Medicare program with Aetna.

Syneos Health Collaborates with AiCure for Patient Engagement

by Zacks Equity Research

Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.

    Here's Why You Should Add NuVasive (NUVA) to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about NuVasive's (NUVA) stellar performance.

    Insulet Rides on Omnipod's Wider Market Reach, New Products

    by Zacks Equity Research

    Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.

      Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod

      by Zacks Equity Research

      The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.

      Globus Medical's U.S. Spine Arm Grows, Product Launches Aid

      by Zacks Equity Research

      Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.

      Hologic's Aptima Genitalium Assay Gets Clinically Verified

      by Zacks Equity Research

      This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.

      Medtronic (MDT) Releases Positive Study Results on Pacemaker

      by Zacks Equity Research

      Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.

      CVS Health's Aetna Prospects Solid, Omnicare Sluggish

      by Zacks Equity Research

      CVS Health's (CVS) strong Pharmacy Services segment sales gain traction from growth in specialty services.

      Zimmer (ZBH) Scales 52-Week High: What's Driving the Stock?

      by Zacks Equity Research

      Zimmer (ZBH) is likely to maintain the current high on a number of favorable factors.

      Myriad Genetics Presents New Test Data in Autoimmune Segment

      by Zacks Equity Research

      Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.

      National Vision's (EYE) Q3 Earnings Top Estimates, View Raised

      by Zacks Equity Research

      National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.

      Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up

      by Zacks Equity Research

      Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.

      Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates

      by Zacks Equity Research

      Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.